Managers / Q3 2025 · view latest →
Altium Capital Management LLC
CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711
Summary
Altium Capital Management LLC reported $628,262 in U.S.-listed holdings across 1 positions for Q3 2025.
The portfolio is heavily concentrated: Plus Therapeutics alone accounts for 100.0% of reported value.
Compared with Q2 2025, the fund opened 2 new positions and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $628,262
Quarter-over-Quarter Changes full breakdown →
vs Q2 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| PLUS THERAPEUTICS INC | NEW | +918.9K | 918.9K | +$628,262 | $628,262 |
| None | NEW | +0 | 0 | +$0 | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | PLUS THERAPEUTICS INC | COM | 100.00% | $628,262 | 918.9K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $42M | 19 | May 1, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $25M | 18 | Feb 6, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $628,262 | 1 | Nov 4, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $42M | 24 | May 13, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2024 | $353M | 67 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $340M | 79 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $245M | 68 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $253M | 72 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $147M | 66 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $192M | 72 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $132M | 68 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $180M | 91 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $197M | 94 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $273M | 134 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $250M | 127 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $299M | 118 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $363M | 133 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $381M | 124 | Nov 17, 2021 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2021 | $431M | 135 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $360M | 124 | May 6, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $268M | 95 | May 5, 2021 | RESTATEMENT | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.